Form 4: Pacira BioSciences Director Acquires Shares in Open Market Purchase

Sentiment:

SEC Form 4 Filing


Director Marcelo Bigal purchased 1,512 shares of Pacira BioSciences (PCRX) at $13.25 per share on August 16, 2024.

Summary

  • On August 16, 2024, Marcelo Bigal, a director of Pacira BioSciences, Inc. (PCRX), acquired 1,512 shares of common stock.
  • The purchase price was $13.25 per share.
  • Following the transaction, Mr. Bigal directly owns 10,142 shares of Pacira BioSciences.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director buying shares suggests confidence, but the purchase is relatively small.

Positives

  • A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director purchases are common and closely watched as indicators of management's sentiment about the company's valuation and prospects. It's a small purchase and may not be indicative of a larger trend.

Stakeholder Impact

  • The stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

DateDescription
08/16/2024Date of stock purchase transaction
08/19/2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.